003520 — Yungjin Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩370bn
- KR₩432bn
- KR₩252bn
- 62
- 10
- 13
- 15
Annual income statement for Yungjin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 208,464 | 196,067 | 218,381 | 234,902 | 252,040 |
| Cost of Revenue | |||||
| Gross Profit | 73,463 | 57,936 | 64,734 | 72,121 | 80,349 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 208,094 | 209,944 | 239,858 | 235,780 | 245,199 |
| Operating Profit | 370 | -13,877 | -21,477 | -877 | 6,841 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 241 | -14,144 | -22,813 | -3,918 | 2,887 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -133 | -11,582 | -21,961 | -3,876 | 1,233 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -133 | -11,582 | -21,961 | -3,876 | 1,233 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -133 | -11,582 | -21,961 | -3,876 | 1,233 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.6 | -62.8 | -68.1 | -5.88 | 11.3 |
| Dividends per Share |